PRESS-RELEASE filed Aug 13, 2026 at 07:30 ET
Ascendis Pharma reported Q2 2026 product revenue of €315M (+105% YoY), driven by YORVIPATH (€252M) and SKYTROFA (€55M), and achieved its first-ever operating profit of €220M (65% margin). The company also settled all $575M in convertible notes, converting them to equity, and reported non-IFRS diluted EPS of €0.90, which is in line with the Street consensus of $0.77 (€0.71), a modest beat. The strong top-line growth and profitability inflection are the key drivers, but the GAAP EPS of €2.83 includes a one-time €158M PRV sale and a €704M deferred tax asset recognition, masking underlying operating leverage.